Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.49 |
| ▸ | CCR7 | P32248 | 3/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497236 | 0.91 | CXCR2 (0.49) | CXCR2CCR7CXCR1 | |
| SCHEMBL3853163 | 0.84 | RAB9A (0.57) | CXCR2CCR7CXCR1 | |
| SCHEMBL3855926 | 0.84 | CXCR2 (0.45) | CXCR2CCR7CXCR1 | |
| SCHEMBL5191224 | 0.80 | CXCR2 (0.69) | CXCR2CCR7 | |
| SCHEMBL490008 | 0.79 | NPC1 (0.48) | CXCR2CCR7CXCR1 | |
| SCHEMBL5951413 | 0.79 | RAB9A (0.51) | CXCR2CCR7CXCR1 | |
| SCHEMBL2899683 | 0.79 | NPC1 (0.48) | CXCR2CCR7CXCR1 | |
| SCHEMBL490245 | 0.78 | CXCR2 (0.50) | CXCR2CCR7 | |
| SCHEMBL490032 | 0.78 | CXCR2 (0.47) | CXCR2CCR7 | |
| SCHEMBL5491796 | 0.77 | CXCR2 (0.45) | CXCR2CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579342-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA (SE) | 2009-08-25 | — | — | US | disclosed |
| US-20060111569-A1 | Thiazolopyrimidines and their use as modulators of chemokine receptor activity | BONNERT ROGER | 2006-05-25 | — | — | US | disclosed |
| US-6958344-B2 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-10-25 | — | — | US | disclosed |
| US-20050234077-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-10-20 | — | — | US | disclosed |
| US-6949643-B2 | Thiazolopytimidines and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-09-27 | — | — | US | disclosed |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-6875868-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2005-04-05 | — | — | US | disclosed |
| EP-1385854-B1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-02-09 | — | — | EP | disclosed |
| US-20040157853-A1 | Thiazolopytimidines and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-08-12 | — | — | US | disclosed |
| EP-1385854-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1259512-B1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| US-20030040523-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1265899-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| EP-1259512-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002083693-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2001062758-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001058902-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111569-A1 | Thiazolopyrimidines and their use as modulators of chemokine receptor activity | CXCR2, CCR5, CXCR1 | CXCR2 1/4885CCR7 16/4885CXCR1 3/4885 |
| US-20040157853-A1 | Thiazolopytimidines and their use as modulators of chemokine receptor activity | CCR5, CCR2, CX3CR1 | CXCR2 5/4885CCR7 17/4885CXCR1 4/4885 |
| US-20030040523-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | CCR5, CXCR1, CXCR4 | CXCR2 4/4885CCR7 13/4885CXCR1 2/4885 |
| US-20050234077-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR2 | CXCR2 3/4885CCR7 12/4885CXCR1 2/4885 |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | CXCR2 1307/4885CCR7 369/4885CXCR1 936/4885 |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | CXCR2 1307/4885CCR7 369/4885CXCR1 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.